产品描述:
Lipoxin A4 (LXA4; Item No. 90410) is a part of the specialized pro-resolving mediator (SPM) family of polyunsaturated fatty acid (PUFA) metabolites.{35079} It is formed from arachidonic acid through double lipoxygenase-catalyzed reactions initiated by either 5-lipoxygenase (5-LO) followed by 12-LO/15-LO, with a leukotriene A4 (LTA4) intermediate, or by 15-LO followed by 5-LO, with 15(S)-HETE and 5(S)-Hp-15(S)-HETE intermediates. The generation of LXA4 typically requires transcellular metabolism of arachidonic acid.{35079,35339} For example, LTA4 that is synthesized in neutrophils by 5-LO is metabolized to LXA4 in platelets by 12-LO.{35339} LXA4 is released during the resolution phase of inflammation and binds to the G protein-coupled LXA4 receptor (ALX)/formyl peptide receptor (FPR2), which is located on leukocytes, and induces cell type-specific signaling.1 In macrophages, it activates phosphatidylinositol 3-kinase (PI3K) and AKT, stimulates non-phlogistic phagocytosis of apoptotic leukocytes, and inhibits apoptosis to prolong the phagocytotic phase.{11078,35388} In neutrophils, it inhibits chemotaxis and transmigration and inhibits production of LTB4 (Item No. 20110).{35389} Cayman’s LXA4 ELISA Kit is a competitive assay which can be used for quantification of LXA4. This assay has been tested in urine, serum, and plasma. The ELISA typically displays an IC50 (50% B/B0) of approximately 200 pg/ml and a detection limit (80% B/B0) of approximately 50 pg/ml.